Đang chuẩn bị liên kết để tải về tài liệu:
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and biomarkers associated with the nanoliposomal irinotecan plus 5-FU/LV regimen. |

TÀI LIỆU LIÊN QUAN

LINC00511 as a prognostic biomarker for human cancers: A systematic review and meta-analysis

Integrative analysis of time course metabolic data and biomarker discovery

Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease

Identification of reproducible gene expression signatures in lung adenocarcinoma

Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer

Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: A meta-analysis

Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer

The role of vascular mimicry as a biomarker in malignant melanoma: A systematic review and meta-analysis

Prognostic and clinicopathological significance of MLKL expression in cancer patients: A meta-analysis

ProtRank: Bypassing the imputation of missing values in differential expression analysis of proteomic data